Company: SCLXW
Filing Date: 2025-12-16
Form Type: S-1
Source: 0001193125-25-319720
Chunk: 641

Company: Scilex Holding Co
Filing Date: 2025-12-16
Form: S-1
Chunk 641
---
 agreement with Datavault (the “Datavault License Agreement”). Under the Datavault License Agreement, among other things, Datavault granted the Company a worldwide, exclusive, non-transferablelicense, with the right to sublicense, under the patents and know-howspecified therein to among other things, research, develop, make, have made, use, sell, have sold, offer for sale, import, export, register, market, promote, advertise, commercialize and distribute the Proprietary Materials (as defined in the Datavault License Agreement, including a suite of patents related to Datavault’s data platforms and any products created therefrom within the Target Market (as defined below). F-106

With respect to the foregoing, “Target Market” shall mean industries including biotechnology, biopharmaceutical, genetic, diagnostic, and data-related industries, and any markets relating to the generation, use, storage, analysis, tokenization, and exchange of DNA, genetic, diagnostic, and therapeutic data or materials. The Datavault License Agreement expires upon the expiry of the patents underlying the Proprietary Materials, at which point the license shall become perpetual, irrevocable, non-exclusiveand royalty-free. The Datavault License Agreement is subject to earlier termination if, among other things: (i) either party ceases to exist or becomes insolvent, (ii) either party commits a material breach of the Datavault License Agreement, (iii) the Company fails to make any required payment to Datavault that is not cured within 15 days, or (iv) the Company does not achieve and maintain annual royalty payments to Datavault of a minimum of $ 1,000,000after 24 months following the date of the Datavault License Agreement. As consideration for the license under the Datavault License Agreement, the Company agreed to pay Datavault (a) a non-refundablelicense fee of $ 10,000,000, payable in four equal installments of $ 2,500,000on or before the last day of each fiscal quarter, beginning on December 31, 2025, (b) subject to achievement of certain net sales for the Licensed Product (as defined therein), up to an aggregate of $ 2,550,000,000, and (c) a five-percent ( 5%) royalty on net sales of the Product (as defined therein) during the applicable royalty term under the Datavault License Agreement. The Dat